MedTrace Logo

An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke

NCT04952064 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2022-09-23

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy and safety of higher doses of monosialoganglioside GM1 injection in the treatment of patients with acute ischemic stroke.

Conditions

  • Stroke, Ischemic

Interventions

DRUG

Monosialoganglioside GM1

Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

Sponsors & Collaborators

  • The Third Xiangya Hospital of Central South University

    collaborator OTHER

  • General Hospital of Shenyang Military Region

    lead OTHER

Principal Investigators

  • Chen Huisheng, Doctor · General Hospital of Shenyang Military Region

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2022-07-18
Completion
2022-07-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04952064 on ClinicalTrials.gov